Results 121 to 130 of about 5,184 (154)

Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir

Viruses, 2022
Karolina Akinosoglou, Georgios Schinas, Akinosoglou Karolina   +2 more
exaly  

Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?

Biomedicine and Pharmacotherapy, 2023
Zatollah Asemi, Michael R Hamblin, Mohammad Yousef Memar   +2 more
exaly  

Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs

Clinical Infectious Diseases, 2023
Louis D Saravolatz, Sharma Mamta
exaly  

Dexamethasone/nirmatrelvir+ritonavir

Reactions Weekly, 2023
openaire   +1 more source

Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)

Clinical Infectious Diseases, 2023
Rockib Uddin, Jonathan Li, Jacob Lemieux   +2 more
exaly  

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS

Pharmaceuticals, 2022

exaly  

Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19

Open Forum Infectious Diseases, 2022
Michael Usher, , Nicolas Hoertel
exaly  

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study

Vaccines, 2022
Riccardo Scotto, Antonio Riccardo Buonomo, Ivan Gentile   +2 more
exaly  

Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry

International Journal of Antimicrobial Agents, 2023
Iker Falces-Romero, Francesco Marchesi, Oliver A Cornely   +2 more
exaly  

The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data

Viruses, 2023
Gregory Trypsianis
exaly